Geri Hart, MD
Family Medicine · Hutchinson, KSNPI 1659463024
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 56.6% of the total. Reporting peaked in 2020 at $1,696 and has fallen 63.6% since, to $617 in 2025.
Across 189 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$480
- Pfizer$237
- AstraZeneca$196
- Sumitomo Pharma America, Inc.$124
- Amgen$84
- plus $578 from 18 others
Across 4 payments — averaging $11,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$44K
What the payments were for
- Speaking & faculty fees$1,57540%
- Travel & lodging$912%
- Food & beverage$2,24957%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $2,215 |
| Novo Nordisk | 40 | $480 |
| Pfizer | 40 | $237 |
| AstraZeneca | 7 | $196 |
| Sumitomo Pharma America, Inc. | 8 | $124 |
| Amgen | 6 | $84 |
| Lilly USA, LLC | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| GSK | 3 | $49 |
| Boehringer Ingelheim | 3 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $39 |
| Bayer | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Abbott | 1 | $15 |
| Merck | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Radius Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,915 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 309 | $156,874 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 490 | $147,783 |
| JanuviaSitagliptin Phosphate | 287 | $139,040 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 626 | $130,864 |
| OzempicSemaglutide | 105 | $127,816 |
| MounjaroTirzepatide | 125 | $125,105 |
| JardianceEmpagliflozin | 173 | $86,290 |
| XareltoRivaroxaban | 90 | $64,790 |
| MyrbetriqMirabegron | 123 | $60,959 |
| GemtesaVibegron | 135 | $50,189 |
| LinzessLinaclotide | 77 | $48,600 |
| FarxigaDapagliflozin Propanediol | 70 | $40,526 |
| TrulicityDulaglutide | 24 | $26,073 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $22,759 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $20,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Nurtec Odt | $237 | $321,820810 claims |
| MerckJanuvia, Janumet, Janumet Xr, Lagevrio (Eua) | $15 | $175,556326 claims |
| Lilly USA, LLCMounjaro, Trulicity | $63 | $151,178149 claims |
| GSKShingrix, Breo Ellipta | $49 | $141,623652 claims |
| Novo NordiskOzempic | $480 | $127,816105 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $44 | $92,588186 claims |
| Johnson & JohnsonXarelto | $13 | $64,79090 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $60,959123 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $124 | $50,189135 claims |
| AbbVieLinzess | $2,215 | $48,60077 claims |
| AstraZenecaFarxiga | $196 | $40,52670 claims |
| BayerKerendia | $30 | $18,00944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Hutchinson
- Matthew SchlotterbackHutchinson$10K
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.